RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human phase 2 evidence

Cagrilintide research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

A multicentre phase 2 trial investigated cagrilintide, a long-acting amylin analogue, using body-mass, safety and tolerability endpoints in adults with overweight or obesity.

Areas studied

  • Amylin-receptor pharmacology
  • Body-mass endpoints
  • Metabolic research
  • Safety and tolerability

Limitations and investigational status

Evidence for cagrilintide alone is led by a sponsor-funded phase 2 trial in a defined clinical population. It does not establish broader outcomes or suitability of research material for human use.

References

  1. 1Lau et al. - The Lancet, 2021

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.